SCHEMBL5876462

SCHEMBL5876462

Cc1ccc(S(=O)(=O)n2nc(NC3CC3)c3c2CC(c2ccccc2)C=C3)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
SLC9A1 P19634 1/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GPR6 P46095 2/20 0.35
GAA P10253 2/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.33
NPY5R Q15761 1/20 0.33
USP2 O75604 1/20 0.33
MAPK1 P28482 1/20 0.33
CCR6 P51684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876033 0.96 MMP2 (0.38) MMP2NPSR1NR1H2NR1H3SMN1; SMN2
SCHEMBL5876671 0.87 NPSR1 (0.40) MMP2NPSR1NR1H2NR1H3SMN1; SMN2
SCHEMBL5876072 0.83 NPSR1 (0.43) MMP2NPSR1NR1H2NR1H3SMN1; SMN2
SCHEMBL5876526 0.81 NPSR1 (0.44) MMP2NPSR1NR1H2NR1H3SMN1; SMN2
SCHEMBL5876012 0.78 NR1H2 (0.36) MMP2NPSR1NR1H2NR1H3SLC9A1
SCHEMBL5877598 0.77 CYP2C19 (0.36) MMP2NPSR1NR1H2NR1H3SLC9A1
SCHEMBL6649960 0.76 MAPT (0.33) NPSR1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6649964 0.75 LMNA (0.32) NPSR1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5876198 0.74 USP2 (0.37) MMP2NPSR1NR1H2NR1H3SLC9A1
SCHEMBL5876220 0.74 NR1H2 (0.34) MMP2NPSR1NR1H2NR1H3SLC9A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed
EP-1414805-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY Aventis Pharma S.A. (FR) 2004-05-06 EP disclosed
WO-2003011833-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY AVENTIS PHARMA S.A. (FR) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT MMP2 3720/4885NPSR1 797/4885NR1H2 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.